Orforglipron vs Retatrutide.

Orforglipron (brand: Foundayo, development code LY3502970) is a once-daily, orally administered GLP-1 receptor agonist developed by Eli Lilly. The FDA approved it on 1 April 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity. It is included on this site despite not being a peptide: orforglipron is a small-molecule, non-peptide agonist of the same receptor the injectable GLP-1 peptides target, and it is the closest direct alternative to them, so leaving it out would misrepresent the landscape people are actually choosing between.

Retatrutide (development code LY3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly for the treatment of obesity and related cardiometabolic disease. It is a single synthetic peptide engineered to act as a "triple G" agonist, simultaneously stimulating three nutrient-hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This distinguishes it from the single agonist semaglutide (GLP-1) and the dual agonist tirzepatide (GIP/GLP-1), both already approved.

Orforglipron binds and activates the GLP-1 receptor, the same class B G-protein-coupled receptor engaged by semaglutide, liraglutide and the GLP-1 arm of tirzepatide, producing glucose-dependent insulin secretion, slowed gastric emptying, suppressed glucagon and reduced appetite. The pharmacologically interesting part is how it does this without being a peptide. Work published in Science Translational Medicine (2024, PMID 39693407) characterises the basis for non-peptide agonism at this receptor: the molecule occupies a site that permits receptor activation from a small synthetic scaffold rather than mimicking the native hormone's full peptide sequence. Because it is not a peptide, it is not degraded in the gut the way oral peptide formulations are, which is why it can be taken as a conventional tablet with no food or water timing restrictions, unlike oral semaglutide.

Retatrutide is a balanced agonist at three receptors, each contributing a distinct metabolic effect. GLP-1 receptor agonism enhances glucose-dependent insulin secretion, slows gastric emptying, and acts centrally to reduce appetite and food intake. GIP receptor agonism further modulates insulin response and appears to improve nutrient handling and tolerability. The defining addition is glucagon receptor agonism, which raises hepatic glucose output and, importantly, increases energy expenditure and promotes hepatic lipid oxidation/mobilization. The combination is intended to layer glucagon-driven increases in energy expenditure and reductions in liver fat on top of the appetite suppression and glycemic benefits of incretin (GLP-1/GIP) signaling. Because glucagon agonism can raise hepatic glucose production and resting heart rate, the receptor balance and dose are designed to keep net effects metabolically favorable.

Human evidence is substantial and spans phase 2 through phase 3 in both obesity and type 2 diabetes. A phase 2 trial in adults with obesity (NEJM 2023, PMID 37351564) established dose-dependent weight reduction, and a parallel phase 2 programme in type 2 diabetes reported in The Lancet (2023, PMID 37369232) showed reductions in HbA1c and body weight. Phase 3 results in obesity were published in the New England Journal of Medicine (2025, PMID 40960239), and a separate NEJM report (2025, PMID 40544435) covered early type 2 diabetes. A head-to-head trial against oral semaglutide in adults with type 2 diabetes appeared in The Lancet (2026, PMID 41765029), and a randomized phase 3 maintenance trial was published in Nature Medicine (2026, PMID 42120723). ACHIEVE-5, adding orforglipron to titrated insulin glargine, was reported in JAMA (2026, PMID 42251769). This is a considerably more complete human evidence package than almost anything else discussed in peptide communities, which is the point worth taking from it.

Human evidence comes from a completed Phase 2 program and emerging Phase 3 data, so this is no longer animal-only, though long-term outcome and safety data remain immature. In the 48-week Phase 2 obesity trial (Jastreboff et al., NEJM 2023), adults with obesity/overweight without diabetes had least-squares mean weight reductions of roughly -17.1%, -22.8%, and -24.2% across higher dose groups versus -2.1% with placebo. A parallel Phase 2 trial in type 2 diabetes (Rosenstock et al., Lancet 2023) showed substantial reductions in HbA1c and body weight. A Phase 2a trial in metabolic dysfunction-associated steatotic liver disease (Nature Medicine 2024) reported large relative reductions in liver fat, with the majority of higher-dose participants reaching liver fat below the steatosis threshold. In May 2026 Lilly reported topline Phase 3 results (TRIUMPH-1, ~2,339 adults), with the highest dose producing about 28.3% mean weight loss at 80 weeks; full peer-reviewed Phase 3 publications and the broader TRIUMPH cardiovascular/diabetes outcome trials were still pending at that time.

The adverse-event profile reported across the trials is the familiar GLP-1 class pattern, dominated by gastrointestinal effects: nausea, vomiting, diarrhoea and constipation, generally most pronounced during dose escalation and often diminishing with time. Discontinuation for gastrointestinal reasons occurred in the trials. As an approved product it carries a prescribing label with the full contraindication and warning set for the GLP-1 receptor agonist class, and that label, not this page, is the authoritative safety document. Because it is a prescription medicine, safety monitoring happens through a prescriber rather than self-management, which is a meaningful difference from the research-use-only compounds elsewhere on this site.

In trials the most common adverse events were gastrointestinal (nausea, vomiting, diarrhea, constipation), dose-related, mostly mild to moderate, and concentrated during dose escalation; using a lower starting dose partially mitigated them. A mechanistically important signal is a dose-dependent increase in heart rate, which in the Phase 2 obesity trial peaked around 24 weeks before declining; glucagon receptor agonism also raises hepatic glucose output, requiring monitoring. Phase 3 topline data showed dose-dependent discontinuation due to adverse events. Because retatrutide is investigational, its long-term safety, cardiovascular outcomes, and effects in broad real-world populations are not yet established. Compounded, "research-use-only," or gray-market retatrutide is not quality-controlled and carries additional, unquantified risks.

FDA-approved 1 April 2026 as Foundayo (orforglipron) for chronic weight management in adults with obesity, or with overweight plus at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity. It is a prescription medicine. Approval is indication-specific: an approval for chronic weight management is not a validation of any other use it may be marketed or discussed for. Regulatory status elsewhere in the world varies and should be checked locally.

As of mid-2026 retatrutide is investigational and not approved by the FDA, EMA, MHRA, or any other regulator for any indication; it remains in Phase 3 development (the TRIUMPH program) by Eli Lilly. It is not a dietary supplement and any product sold as "research-use-only" retatrutide is unapproved.